STOCK TITAN

[8-K] Stryker Corporation Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

On 31 Jul 2025 The Clorox Company (NYSE: CLX) filed a Form 8-K to furnish its fiscal Q4 and full-year 2025 results under Item 2.02 and to provide supplemental information under Item 7.01. While the filing references the earnings press release (Exhibit 99.1) and detailed schedules (Exhibit 99.2), no quantitative data (revenue, EPS, margin, guidance) are included in the body of the report itself; investors must review the exhibits for specifics.

No other corporate events—such as acquisitions, restructurings, capital actions or leadership changes—are disclosed. The document’s primary purpose is to place the earnings materials into the public domain and satisfy SEC disclosure requirements; market impact therefore depends entirely on the financial figures contained in the attached exhibits, not on the 8-K narrative.

Il 31 luglio 2025 The Clorox Company (NYSE: CLX) ha presentato un modulo 8-K per comunicare i risultati del quarto trimestre fiscale e dell'intero anno 2025 ai sensi del punto 2.02 e per fornire informazioni supplementari ai sensi del punto 7.01. Sebbene il documento faccia riferimento al comunicato stampa sugli utili (Allegato 99.1) e ai dettagliati prospetti (Allegato 99.2), nel corpo del rapporto non sono inclusi dati quantitativi (ricavi, EPS, margini, previsioni); gli investitori devono consultare gli allegati per i dettagli specifici.

Non vengono divulgati altri eventi aziendali, come acquisizioni, ristrutturazioni, operazioni sul capitale o cambiamenti nella leadership. Lo scopo principale del documento è rendere pubblici i materiali sugli utili e soddisfare i requisiti di divulgazione della SEC; l'impatto sul mercato dipende quindi esclusivamente dai dati finanziari contenuti negli allegati, non dal testo del modulo 8-K.

El 31 de julio de 2025, The Clorox Company (NYSE: CLX) presentó un Formulario 8-K para informar sus resultados del cuarto trimestre fiscal y del año completo 2025 según el ítem 2.02, y para proporcionar información complementaria según el ítem 7.01. Aunque el informe hace referencia al comunicado de prensa de ganancias (Exhibición 99.1) y a los cronogramas detallados (Exhibición 99.2), no se incluyen datos cuantitativos (ingresos, BPA, margen, previsiones) en el cuerpo del informe; los inversores deben revisar las exhibiciones para obtener detalles específicos.

No se divulgan otros eventos corporativos, como adquisiciones, reestructuraciones, acciones de capital o cambios en el liderazgo. El propósito principal del documento es poner los materiales de ganancias en el dominio público y cumplir con los requisitos de divulgación de la SEC; por lo tanto, el impacto en el mercado depende completamente de las cifras financieras contenidas en las exhibiciones adjuntas, no de la narrativa del 8-K.

2025년 7월 31일, The Clorox Company(NYSE: CLX)는 항목 2.02에 따라 2025 회계연도 4분기 및 전체 연도 실적을 제공하고, 항목 7.01에 따라 보충 정보를 제공하기 위해 Form 8-K를 제출했습니다. 제출서에는 실적 보도자료(첨부문서 99.1)와 상세 일정표(첨부문서 99.2)가 언급되어 있으나, 보고서 본문에는 수익, 주당순이익, 마진, 가이던스 등 정량적 데이터가 포함되어 있지 않으므로 투자자들은 구체적인 내용을 확인하기 위해 첨부문서를 검토해야 합니다.

인수, 구조조정, 자본 조치 또는 경영진 변경과 같은 다른 기업 이벤트는 공개되지 않았습니다. 이 문서의 주요 목적은 실적 자료를 공개하고 SEC 공시 요건을 충족하는 데 있으며, 시장에 미치는 영향은 8-K 본문 내용이 아닌 첨부된 재무 수치에 전적으로 의존합니다.

Le 31 juillet 2025, The Clorox Company (NYSE : CLX) a déposé un formulaire 8-K pour communiquer ses résultats du quatrième trimestre fiscal et de l'année complète 2025 conformément à l'article 2.02, ainsi que pour fournir des informations complémentaires selon l'article 7.01. Bien que le dépôt fasse référence au communiqué de presse sur les résultats (Exhibit 99.1) et aux annexes détaillées (Exhibit 99.2), aucun chiffre quantitatif (chiffre d'affaires, BPA, marge, prévisions) n'est inclus dans le corps du rapport ; les investisseurs doivent consulter les annexes pour les détails spécifiques.

Aucun autre événement d'entreprise — tel que des acquisitions, des restructurations, des opérations sur le capital ou des changements de direction — n'est divulgué. L'objectif principal du document est de rendre publics les documents relatifs aux résultats et de satisfaire aux exigences de divulgation de la SEC ; l'impact sur le marché dépend donc entièrement des chiffres financiers contenus dans les annexes jointes, et non du contenu narratif du 8-K.

Am 31. Juli 2025 reichte The Clorox Company (NYSE: CLX) ein Formular 8-K ein, um die Ergebnisse des vierten Quartals und des Gesamtjahres 2025 gemäß Punkt 2.02 vorzulegen und ergänzende Informationen gemäß Punkt 7.01 bereitzustellen. Obwohl die Einreichung auf die Gewinnmitteilung (Anlage 99.1) und detaillierte Zeitpläne (Anlage 99.2) verweist, sind im Berichtstext keine quantitativen Daten (Umsatz, Ergebnis je Aktie, Marge, Prognosen) enthalten; Investoren müssen die Anlagen für Details prüfen.

Es werden keine weiteren Unternehmensereignisse wie Übernahmen, Umstrukturierungen, Kapitalmaßnahmen oder Führungswechsel offengelegt. Der Hauptzweck des Dokuments besteht darin, die Gewinnmaterialien öffentlich zugänglich zu machen und die Offenlegungspflichten der SEC zu erfüllen; die Marktreaktion hängt daher ausschließlich von den in den beigefügten Anlagen enthaltenen Finanzzahlen ab, nicht vom Text des 8-K-Berichts.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Procedural 8-K—earnings exhibits attached, no numbers inside; impact depends on figures not shown here.

Because the core financial metrics are only embedded in Exhibits 99.1 and 99.2, the filing itself offers no basis to revise estimates or valuation. Investors must consult the press release to assess sales trends, margins, pricing or FY26 guidance. From a trading perspective, the 8-K per se is neutral; price reaction will hinge on the separate earnings data.

TL;DR: Standard compliance filing; demonstrates timely disclosure, no governance red flags detected.

Clorox met its reporting obligations by promptly furnishing the earnings release via Form 8-K. Inclusion of supplemental schedules improves transparency. There are no indications of restatements, internal-control issues, or unusual board actions. Accordingly, governance risk remains unchanged and impact is minimal.

Il 31 luglio 2025 The Clorox Company (NYSE: CLX) ha presentato un modulo 8-K per comunicare i risultati del quarto trimestre fiscale e dell'intero anno 2025 ai sensi del punto 2.02 e per fornire informazioni supplementari ai sensi del punto 7.01. Sebbene il documento faccia riferimento al comunicato stampa sugli utili (Allegato 99.1) e ai dettagliati prospetti (Allegato 99.2), nel corpo del rapporto non sono inclusi dati quantitativi (ricavi, EPS, margini, previsioni); gli investitori devono consultare gli allegati per i dettagli specifici.

Non vengono divulgati altri eventi aziendali, come acquisizioni, ristrutturazioni, operazioni sul capitale o cambiamenti nella leadership. Lo scopo principale del documento è rendere pubblici i materiali sugli utili e soddisfare i requisiti di divulgazione della SEC; l'impatto sul mercato dipende quindi esclusivamente dai dati finanziari contenuti negli allegati, non dal testo del modulo 8-K.

El 31 de julio de 2025, The Clorox Company (NYSE: CLX) presentó un Formulario 8-K para informar sus resultados del cuarto trimestre fiscal y del año completo 2025 según el ítem 2.02, y para proporcionar información complementaria según el ítem 7.01. Aunque el informe hace referencia al comunicado de prensa de ganancias (Exhibición 99.1) y a los cronogramas detallados (Exhibición 99.2), no se incluyen datos cuantitativos (ingresos, BPA, margen, previsiones) en el cuerpo del informe; los inversores deben revisar las exhibiciones para obtener detalles específicos.

No se divulgan otros eventos corporativos, como adquisiciones, reestructuraciones, acciones de capital o cambios en el liderazgo. El propósito principal del documento es poner los materiales de ganancias en el dominio público y cumplir con los requisitos de divulgación de la SEC; por lo tanto, el impacto en el mercado depende completamente de las cifras financieras contenidas en las exhibiciones adjuntas, no de la narrativa del 8-K.

2025년 7월 31일, The Clorox Company(NYSE: CLX)는 항목 2.02에 따라 2025 회계연도 4분기 및 전체 연도 실적을 제공하고, 항목 7.01에 따라 보충 정보를 제공하기 위해 Form 8-K를 제출했습니다. 제출서에는 실적 보도자료(첨부문서 99.1)와 상세 일정표(첨부문서 99.2)가 언급되어 있으나, 보고서 본문에는 수익, 주당순이익, 마진, 가이던스 등 정량적 데이터가 포함되어 있지 않으므로 투자자들은 구체적인 내용을 확인하기 위해 첨부문서를 검토해야 합니다.

인수, 구조조정, 자본 조치 또는 경영진 변경과 같은 다른 기업 이벤트는 공개되지 않았습니다. 이 문서의 주요 목적은 실적 자료를 공개하고 SEC 공시 요건을 충족하는 데 있으며, 시장에 미치는 영향은 8-K 본문 내용이 아닌 첨부된 재무 수치에 전적으로 의존합니다.

Le 31 juillet 2025, The Clorox Company (NYSE : CLX) a déposé un formulaire 8-K pour communiquer ses résultats du quatrième trimestre fiscal et de l'année complète 2025 conformément à l'article 2.02, ainsi que pour fournir des informations complémentaires selon l'article 7.01. Bien que le dépôt fasse référence au communiqué de presse sur les résultats (Exhibit 99.1) et aux annexes détaillées (Exhibit 99.2), aucun chiffre quantitatif (chiffre d'affaires, BPA, marge, prévisions) n'est inclus dans le corps du rapport ; les investisseurs doivent consulter les annexes pour les détails spécifiques.

Aucun autre événement d'entreprise — tel que des acquisitions, des restructurations, des opérations sur le capital ou des changements de direction — n'est divulgué. L'objectif principal du document est de rendre publics les documents relatifs aux résultats et de satisfaire aux exigences de divulgation de la SEC ; l'impact sur le marché dépend donc entièrement des chiffres financiers contenus dans les annexes jointes, et non du contenu narratif du 8-K.

Am 31. Juli 2025 reichte The Clorox Company (NYSE: CLX) ein Formular 8-K ein, um die Ergebnisse des vierten Quartals und des Gesamtjahres 2025 gemäß Punkt 2.02 vorzulegen und ergänzende Informationen gemäß Punkt 7.01 bereitzustellen. Obwohl die Einreichung auf die Gewinnmitteilung (Anlage 99.1) und detaillierte Zeitpläne (Anlage 99.2) verweist, sind im Berichtstext keine quantitativen Daten (Umsatz, Ergebnis je Aktie, Marge, Prognosen) enthalten; Investoren müssen die Anlagen für Details prüfen.

Es werden keine weiteren Unternehmensereignisse wie Übernahmen, Umstrukturierungen, Kapitalmaßnahmen oder Führungswechsel offengelegt. Der Hauptzweck des Dokuments besteht darin, die Gewinnmaterialien öffentlich zugänglich zu machen und die Offenlegungspflichten der SEC zu erfüllen; die Marktreaktion hängt daher ausschließlich von den in den beigefügten Anlagen enthaltenen Finanzzahlen ab, nicht vom Text des 8-K-Berichts.

false000031076400003107642025-07-312025-07-310000310764us-gaap:CommonStockMember2025-07-312025-07-310000310764syk:SeniorUnsecuredNotes2.125Due2027Member2025-07-312025-07-310000310764syk:SeniorUnsecuredNotes3.375Due2028Member2025-07-312025-07-310000310764syk:SeniorUnsecuredNotes0.750Due2029Member2025-07-312025-07-310000310764syk:SeniorUnsecuredNotes2.625Due2030Member2025-07-312025-07-310000310764syk:SeniorUnsecuredNotes1.000Due2031Member2025-07-312025-07-310000310764syk:SeniorUnsecuredNotes3.375Due2032Member2025-07-312025-07-310000310764syk:SeniorUnsecuredNotes3.625Due2036Member2025-07-312025-07-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 31, 2025
strykerlogoa70.jpg
STRYKER CORPORATION
(Exact name of registrant as specified in its charter)
Michigan001-1314938-1239739
(State of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)
1941 Stryker Way Portage,Michigan49002
(Address of principal executive offices)(Zip Code)
(269)385-2600
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.10 Par ValueSYKNew York Stock Exchange
2.125% Notes due 2027SYK27New York Stock Exchange
3.375% Notes due 2028SYK28New York Stock Exchange
0.750% Notes due 2029SYK29New York Stock Exchange
2.625% Notes due 2030SYK30New York Stock Exchange
1.000% Notes due 2031SYK31New York Stock Exchange
3.375% Notes due 2032SYK32New York Stock Exchange
3.625% Notes due 2036SYK36New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    



ITEM 2.02RESULTS OF OPERATIONS AND FINANCIAL CONDITION

Stryker Corporation issued a press release on July 31, 2025 announcing its second quarter 2025 operating results. A copy of this press release is attached hereto as Exhibit 99.1.

The information furnished in this report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS
(d)Exhibits
99.1
Stryker reports second quarter 2025 operating results, press release dated July 31, 2025
104Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
STRYKER CORPORATION
(Registrant)
Date:July 31, 2025/s/ PRESTON W. WELLS
Preston W. Wells
Vice President, Chief Financial Officer

FAQ

When did Clorox (CLX) file its latest Form 8-K?

The company filed the Form 8-K on July 31, 2025.

What items are covered in Clorox’s July 31 2025 Form 8-K?

The filing covers Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD disclosure).

Where can investors find Clorox’s Q4 FY25 financial figures?

Detailed numbers are in Exhibit 99.1 (press release) and Exhibit 99.2 (supplemental tables) attached to the 8-K.

Did the 8-K report any mergers, leadership changes or legal issues?

No. The document only furnishes earnings information; it reports no other material corporate events.
Stryker Corp

NYSE:SYK

SYK Rankings

SYK Latest News

SYK Latest SEC Filings

SYK Stock Data

153.02B
361.26M
5.38%
79.94%
1.24%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PORTAGE